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hypnale) bite: a case report
Milinda Withana1, Chaturaka Rodrigo2*, Ariaranee Gnanathasan2 and Lallindra Gooneratne3Abstract
Hump-nosed viper bites are frequent in southern India and Sri Lanka. However, the published literature on this
snakebite is limited and its venom composition is not well characterized. In this case, we report a patient with
thrombotic thrombocytopenic purpura-like syndrome following envenoming which, to the best of our knowledge,
has not been reported in the literature before. A 55-year-old woman from southern Sri Lanka presented to the local
hospital 12 hours after a hump-nosed viper (Hypnale hypnale) bite. Five days later, she developed a syndrome that
was characteristic of thrombotic thrombocytopenic purpura with fever, thrombocytopenia, microangiopathic
hemolysis, renal impairment and neurological dysfunction in the form of confusion and coma. Her clinical syndrome
and relevant laboratory parameters improved after she was treated with therapeutic plasma exchange. We compared
our observations on this patient with the current literature and concluded that thrombotic thrombocytopenic purpura
is a theoretically plausible yet unreported manifestation of hump-nosed viper bite up to this moment. This study also
provides an important message for clinicians to look out for this complication in hump-nosed viper bites since timely
treatment can be lifesaving.
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Hump-nosed vipers of the genus Hypnale have three
species Hypnale hypnale (Figure 1), Hypnale nepa and
Hypnale zara [1]. Their geographical distribution includes
mainly Sri Lanka and south western India [2]. Hump-
nosed viper bites are the commonest cause of snake en-
venoming in Sri Lanka accounting for 22 to 77% of all
snakebites in different series [3]. Bites are characterized by
local inflammation, blistering and tissue necrosis. Systemic
envenoming may cause coagulopathy, acute kidney injury
and death [1]. Thrombotic microangiopathy (TMA) is one
of the proposed pathophysiological mechanisms for its
systemic complications [4]. Still, the pathophysiologically
related thrombotic thrombocytopenic purpura (TTP) as a
complication of snake envenoming has never been re-
ported in the medical literature.* Correspondence: chaturaka.rodrigo@gmail.com
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unless otherwise stated.Since TTP has high mortality without prompt recogni-
tion and treatment, awareness about this potential com-
plication associated with hump-nosed viper envenoming
is lifesaving. Currently there is no licensed antivenom
for hump-nosed viper bites in Sri Lanka. The polyspe-
cific antivenom currently available in Sri Lanka is im-
ported from India – which is manufactured against the
Indian species of cobra, Russell’s viper, common krait
and saw-scaled viper venom – and does not have anti-
bodies against hump-nosed viper venom. Hence, it is
ineffective against hump-nosed viper venom and po-
tentially dangerous due to anaphylactic reactions. There-
fore, treatment is restricted to supportive care.Case presentation
A 55-year-old woman from a rural area of the Southern
Province of Sri Lanka presented to the local hospital
12 hours after a snakebite on her left foot. On admis-
sion, she had swelling and blistering below the left ankle.
The snake was killed and brought to hospital where itl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The hump-nosed viper (Hypnale hypnale).
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viper (Hypnale hypnale) and subsequently confirmed by
one of the authors of this study (AG). Her medical his-
tory had been unremarkable until this admission and
she was not on any long-term medication. The patient
was fully conscious, alert and oriented at the admission.
There was swelling and blistering on the dorsum of the
left foot with two distinct fang marks below the left lat-
eral malleolus. Findings on the rest of her physical exa-
mination were unremarkable. A twenty-minute whole
blood clotting test (20WBCT) was normal at admission
indicating there was no coagulopathy at that point. The
initial screening of liver enzymes, prothrombin time and
serum creatinine were within reference range.
After three days of admission, the patient became un-
well with oliguria and serum creatinine began to rise
(Figure 2). Hemodialysis was initiated on day 5 (date of
snakebite taken as day 0) due to oliguric acute kidney in-
jury. She became confused at this point and deteriorated
rapidly within the next 24 hours with reduced level of
consciousness. The Glasgow coma scale on day 6 was
7/15 (E2, V2, M3). She had also developed pyrexia at this
point with a core temperature of 38.8°C. The patient wasFigure 2 Change in serum creatinine level of the patient during her hunable to protect her airway and was moved to the med-
ical intensive care unit following elective endotracheal
intubation in the ward.
At this point it was observed that the platelet count
had progressively dropped since admission (Figure 3). It
was 88,000/μL (ref. range: 150,000-450,000) by day 5.
Changes in red cell concentration and haemoglobin con-
centration at this time are shown in Figure 4. Blood film
taken on same day showed features of microangiopathic
hemolysis (fragmented red cells) but coagulation param-
eters were unaltered; prothrombin time was 13.4 seconds
(9.6-13.6), international normalized ratio (INR) was 1.2,
activated partial thromboplastin time was 27 seconds
(24-36), plasma fibrinogen level was 3.2 g/L (1.5-4.5)
and D-dimer level was 0.4 mg/L (<0.2 mg/L). Direct and
indirect Coombs’ tests were negative. Thromboelasto-
metry results (clotting time, clot formation time, α angle
and maximum clot firmness) also remained within nor-
mal limits despite thrombocytopenia. A possible expla-
nation is that the pro-thrombotic state which exists in
thrombotic microangiopathies negated the “tendency to
bleed” due to thrombocytopenia.
Other investigation results at this point were as fol-
lows: serum aspartate aminotransferase (AST) 36 U/L
(reference range: 10-35), alanine aminotransferase (ALT)
39 U/L (10-40), alkaline phosphatase 199 U/L (100-360),
total bilirubin 38 μmol/L (5-21) (direct fraction 15%),
serum ionized calcium 1.2 mmol/L (1-1.3), phosphorus
1.5 mmol/L (0.8-1.5), and magnesium 0.7 mmol/L (0.8-1.1).
Blood and urine cultures were sterile. Non-contrast en-
hanced computed tomography of brain revealed no ab-
normalities. Magnetic resonance imaging of brain after
gadolinium contrast revealed high T2 signal intensities
in bilateral periventricular white matter without signifi-
cant diffusion abnormalities. This was suggestive of white
matter ischaemia or cerebral edema.ospital stay.
Figure 3 Change in platelet count of the patient during the first 35 days of hospital stay (TPE – therapeutic plasma exchange).
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tate dehydrogenase levels were significantly elevated
(1660 IU/L, reference range 230-460). The overall pic-
ture suggested a diagnosis of thrombotic thrombocytope-
nic purpura (TTP). Despite this complication has never
been reported following snakebite, we initiated thera-
peutic plasma exchange with fresh frozen plasma on
day 7. Plasma exchange is the standard treatment for
TTP and it was carried out at a frequency of one cycle
every 48 hours. Following the third cycle of TPE, there was
a gradual improvement in the level of consciousness, but
the thrombocytopenia and features of microangiopathic
hemolysis (MAHA) in blood film continued. After the se-
venth cycle of TPE there was a sustained rise in platelet
count and features of MAHA gradually disappeared.Figure 4 Change in red cell count and hemoglobin during the first 35In the meantime, fourteen sessions of intermittent
hemodialysis were carried out over six weeks, which led
to a sustained improvement in renal functions. Her stay
in the intensive care unit was also complicated by a
ventilator-associated pneumonia and difficulty in wea-
ning from the ventilator. With intense supportive care,
intravenous antibiotics and chest physiotherapy, the pa-
tient made a full recovery and was discharged from
the hospital on day 65. The platelet count picked up to
250,000/μL, lactate dehydrogenase level and other bio-
chemical parameters such as liver and renal function tests
were within normal limits at the point of discharge. She
was clinically well and gradually returning to her daily
routine at home two weeks later in the follow up clinic.
She was subsequently discharged from our clinic to bedays of hospital stay (TPE – therapeutic plasma exchange).
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renal functions as cortical necrosis and chronic kidney
disease, a potential complication of hump-nosed viper
bites.
Discussion
Adult TTP is an acute syndrome that comprises throm-
bocytopenia and microangiopathic hemolytic anemia
associated with fever, varying degree of neurological
dysfunction and renal impairment [5]. TTP exists in a
spectrum with its counterpart hemolytic uremic syn-
drome (HUS). When the neurological impairment is a
prominent manifestation, a diagnosis of TTP is favored,
and if the renal impairment is prominent, HUS is favored
[5]. Our patient had features of both these syndromes but
it is not surprising as TTP and HUS are not mutually ex-
clusive. They exist in a spectrum with either entity being
at the two extremes. So, there can be patients with a
mixed picture.
Most cases of TTP are associated with a deficiency of
the metalloproteinase ADAMTS 13, which is responsible
for cleavage of unusually large von Willebrand factor
multimers in plasma. Its deficiency results in accumula-
tion of these multimers giving rise to platelet aggregation,
microthrombi formation and thrombotic microangiopathy
[5]. Still, TTP can be observed in patients with normal
ADAMTS 13 levels and a proposed hypotheses for patho-
genesis in these circumstances include endothelial injury,
increased platelet aggregation and increased levels of
plasminogen-activator inhibitor type 1 (PAI-1). Acquired
causes for adult TTP-HUS spectrum include bloody diar-
rheas associated with shiga toxin-producing E. coli, drugs
(e.g. quinine, mitomycin, tacrolimus, sirolimus, cyclos-
porine), pregnancy and autoimmune diseases such as
systemic lupus erythematosus. While primary or con-
genital cases of TTP are associated with a reduced level of
ADAMTS 13, certain secondary causes of TTP may have
normal levels of the enzyme [6,7].
Venom induced consumptive coagulation (VICC) is
a well-known consequence of viper bites [8]. It is also
known that some viper venoms, such as those of hump-
nosed viper and Russell’s viper, can precipitate renal
failure. The common tendency is to view both these
manifestations as a part of a same syndrome. VICC is
characterized by rapid onset coagulopathy within hours
after the snake bite with elevated D-dimer levels, pro-
longed prothrombin time, and low fibrinogen levels which
at times is associated with thrombocytopenia [9]. This re-
solves within 24 to 48 hours. It is not associated with sys-
temic micro-thrombi and end-organ failure [9]. In two
series of hump-nosed viper bites in Sri Lanka, coagulopa-
thy was observed in only 21-39% of the sample [3,10].
Current evidence suggests that VICC and mechanisms of
end organ damage – such as renal failure – are mutuallyexclusive though they can co-exist. It also follows that one
can occur in absence of the other. That will explain the
situation with our patient in which end organ failure was
observed without any evidence of VICC.
This leads us to the question of the actual pathophysi-
ology of end organ damage (which is renal failure in
most occasions) in hump-nosed viper bites. It is thought
to be due to venom induced thrombotic microangiopa-
thy (TMA) [4,11]. It has also been suggested that TMA
follows VICC in a subset of patients implicating the
same toxin mediated pathology for both conditions [9].
What is interesting with this picture is that TTP-HUS
spectrum is also characterized by thrombotic microangi-
opathy. The more frequent renal failure observed with
hump-nosed viper bites is probably not often linked to
HUS as there is no coagulopathy in this syndrome
(which is frequently observed and mistakenly thought to
be linked to renal failure in viper bites). However, if we
follow the evidence that VICC is unrelated to organ fail-
ure and TMA can happen without VICC by a separate
mechanism, then an acquired HUS-like syndrome will
explain the clinical picture seen in patients with renal
failure after a hump-nosed viper bite [12]. It also follows
that if HUS-like manifestations may occur in a victim,
TTP-like manifestations may also occur as a part of the
same spectrum. Strangely, although renal failure is fre-
quently reported secondary to microangiopathy (HUS
equivalent), a TTP-like syndrome has never been re-
ported. One reason may be that it is extremely rare to
get a patient at the TTP end of the spectrum compared
to the HUS end. Another reason may be that physicians
confuse TMA and VICC (which may co-exist by inde-
pendent mechanisms) to be a part of the same syndrome
and misdiagnose the patient as having disseminated intra-
vascular coagulation (DIC) [9]. So any TTP-like symptoms
(confusion, seizures) may be attributed to DIC. This can
result in inappropriate management strategies that can
potentially harm the patient.
Though not exactly fitting to a diagnosis of TTP, syn-
dromes suggestive of TTP-HUS spectrum has been re-
ported in the literature with other venomous animal bites
and stings [13-15]. Ho et al. [16] report an interesting case
of tiger snake (Notechis scutatus) envenoming in which
the patient had a somewhat similar course of illness to
our patient. After an initial VICC, the patient had acute
renal failure and a high LDH level with normal coagula-
tion parameters. There was also microangiopathic hemo-
lysis that followed resolution of VICC. The ADAMTS 13
levels, however, were normal and the patient did not have
other clinical features of TTP. This patient received anti-
venom and also underwent plasmapheresis with subse-
quent recovery. However, the authors wondered, since
ADAMTS 13 levels were normal, whether plasmapheresis
was of any benefit. This observation has also been made
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snake envenoming.
In our opinion, the data is not adequate to either con-
firm or refute the role of plasmapheresis in similar cir-
cumstances. Different envenoming may induce different
patterns of clinical syndromes and it may be dangerous
to generalize that in all or most snakebites ADAMTS 13
levels are normal. It is simply unknown and further data
is necessary for each species. For example, envenoming
by the scorpion Hemiscorpius lepturus is known to pro-
duce an HUS-like syndrome with low ADAMTS 13 levels
and increased anti-ADAMTS 13 antibodies [14]. Further-
more, the clinical syndrome in our patient resembled
more a classical picture of TTP than the patients cited in
other case reports and there was no specific antivenom
available. This justified our decision to go ahead with
plasmapheresis based on the clinical picture, which re-
sulted in a positive outcome. Unfortunately measuring
ADAMTS 13 levels is a costly technique that is available
in reference laboratories and currently not available to us
in Sri Lanka. Given the increasing number of patients
with acute renal failure and microangiopathy following
Hypnale bites, data on ADAMTS 13 levels in Hypnale sp.
envenoming should be a focus for further research.
Limitations
As mentioned above we could not measure the ADAMTS
13 levels in this patient as the assay was unavailable. It is
also possible that the renal failure in this patient occurred
via an independent mechanism to TMA such as venom
induced acute tubular necrosis. It is noted that the TTP-
like syndrome (explainable by TMA) resolved rapidly with
plasma exchange but the renal impairment took nearly six
weeks to improve.
Conclusions
Our patient is an excellent case to support the hypoth-
esis that TMA in hump-nosed viper bites may occur in
absence of VICC. Their origins may be related, but are
independent. The manifestations of TMA favored a
TTP-like syndrome rather than a HUS-like syndrome as
she had all five classical features of TTP: fever, thrombo-
cytopenia, microangiopathic hemolysis, renal impairment
and neurological dysfunction (in the form of confusion
and coma). Her clinical syndrome and relevant laboratory
parameters improved after she was treated as for TTP.
This unique case of a never before reported manifestation
of hump-nosed viper envenoming encourages us to re-
think about our current understanding of venom patho-
physiology. The literature on this snake is sparse as bites
are reported from a restricted geographical area (southern
India and Sri Lanka). Our observations fit with the current
thinking of venom toxinology and go one step further to
show that a hitherto unknown, but theoretically plausible,life-threatening manifestation had actually occurred in real
life. This case report also has an important message for
clinicians to look out for a TTP-like syndrome in hump-
nosed viper bites and not to confuse it with DIC. Appro-
priate timely treatment can be lifesaving.
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